Vicapsys Life Sciences, Inc. (VICP) stock
Close on Oct 19, 2026Market cap $13.73MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2024
Valuation
- Market cap
- $13.73M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$1.35M
- EPS, diluted
- -$0.05
- Book value per share
- -$0.08
- Diluted shares
- 34M
Trading
- Previous close
- $0.40
- Open
- $0.40
- Day's range
- $0.40 – $0.40
- Volume
- 0
- Average volume (20 days)
- 4,245
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | VICP | S&P 500 | Difference | VICP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -52.9% | +0.6% | −53.6 pts | ||
| 3 months | -72.6% | +3.4% | −76.0 pts | ||
| Year to date | -73.3% | +13.3% | −86.6 pts | ||
| 1 year | -77.4% | +16.6% | −94.0 pts | ||
| 3 years | -86.7% | +86.4% | −173.0 pts | -48.9% | +23.1% |
| 5 years | +60.0% | +81.9% | −21.9 pts | +9.9% | +12.7% |
| 10 years | -60.0% | +318.9% | −378.9 pts | -8.8% | +15.4% |
Six years at a glance
Fiscal years 2018 to 2023 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Vicapsys Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K
About Vicapsys Life Sciences
Pharmaceutical Preparations
Vicapsys Life Sciences, Inc. is a preclinical biotechnology company focused on developing and commercializing therapeutic technologies that create zones of immunoprotection. Utilizing proprietary derivatives of the chemokine CXCL12 licensed from Massachusetts General Hospital, the company designs encapsulated product candidates to shield transplanted cells, tissues, organs, and medical devices from immune destruction and fibrotic encapsulation. Its development pipeline includes VICAPSYN, an encapsulated human islet cell cluster designed for transplantation therapies to treat patients suffering from Type 1 diabetes, and VYBRIN, an anti-fibrotic product candidate being explored to prevent post-surgical abdominal adhesions, coat implantable medical devices, and promote diabetic ulcer wound healing.
Company profile, executives and historyVicapsys Life Sciences stock: common questions
What is Vicapsys Life Sciences's stock price?
VICP closed at $0.40 on Oct 19, 2026, up 0.00% on the day.
What is Vicapsys Life Sciences's market cap?
Vicapsys Life Sciences was worth $13.73M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is VICP's P/E ratio?
Vicapsys Life Sciences lost money over the twelve months to Sep 30, 2024 (diluted EPS -$0.05), so it has no meaningful P/E ratio.
Does Vicapsys Life Sciences pay a dividend?
No. Vicapsys Life Sciences has not paid a cash dividend over the last twelve months.
How has VICP stock performed over the past year?
Including dividends, VICP returned -77.4% over the past year, against +16.6% for the S&P 500.
Who are Vicapsys Life Sciences's competitors?
Companies most similar to Vicapsys Life Sciences by business, industry and size include BIXT, FBLG, ELDN, GALT, SKYE.
See a number that looks wrong?